Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01788683 · ClinicalTrials.gov registry record · NA

Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears

A NA study of Rotator Cuff Tear, sponsored by Regenexx.

Completed
Registry status
NA
Development phase
51
Enrollment target
1
Study location

NCT01788683 is a NA study of Rotator Cuff Tear that has completed, run by Regenexx. The registered enrollment target is 51 participants, below the 89-participant average among 11 other Rotator Cuff Tear trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01788683, a NA study of Rotator Cuff Tear, has completed, sponsored by Regenexx.

COMPLETED
Registry status
NA
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes, for Regenexx SD treatment vs. Exercise Therapy of non-retracted supraspinatus tendon tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months. Secondary objectives include evaluation of US evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

Conditions Studied

Interventions

  • PROCEDURE Regenexx SD
  • OTHER Exercise Therapy

Study Locations (1)

Colorado

  • Centeno-Schultz Clinic - Broomfield

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2013-02
Est. Completion 2022-07-28
Phase NA

Sponsor

Regenexx

13 total trials

What the Registry Record Tells You About NCT01788683

The ClinicalTrials.gov registry entry for NCT01788683 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 11 other Rotator Cuff Tear trials with a reported enrollment target (43% lower). The listed sponsor is Regenexx, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rotator Cuff Tear appearing as the primary indexed condition, and to 2 interventions - of which Regenexx SD is the first listed.

NCT01788683 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT01788683 about?

NCT01788683 is a clinical study titled "Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears". The primary objective of this study is to compare the improvement in subject-reported clinical outcomes, for Regenexx SD treatment vs. Exercise Therapy of non-retracted supraspinatus tendon tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months. Secon...

What is the current status of trial NCT01788683?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2013-02. Estimated completion is 2022-07-28.

What conditions does trial NCT01788683 study?

This clinical trial studies the following conditions: Rotator Cuff Tear.

What interventions are being tested in trial NCT01788683?

The interventions under investigation include: Regenexx SD (PROCEDURE), Exercise Therapy (OTHER).

Who is sponsoring clinical trial NCT01788683?

This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01788683 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rotator Cuff Tear

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.